LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
Rhea-AI Summary
LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical stage pharmaceutical company, has announced a significant update to its corporate treasury policy to include cryptocurrency investments. The company's Board of Directors has approved allocating up to 25% of its treasury to cryptocurrencies, primarily Bitcoin and potentially other digital assets.
The implementation will be strategic, with timing and size of transactions dependent on market conditions. LIXTE plans to utilize regulated custodians for asset storage and will maintain strict compliance with financial, legal, and audit regulations. CEO Geordan Pursglove emphasized this move as a strategy to hedge existing treasury assets and enhance shareholder value.
Positive
- Strategic diversification of treasury assets into cryptocurrency
- Conservative approach with maximum 25% allocation limit
- Commitment to using regulated custodians and maintaining compliance
- Potential for enhanced returns and inflation hedging
Negative
- Exposure to highly volatile cryptocurrency market
- Potential regulatory risks associated with crypto holdings
- Significant portion (25%) of treasury exposed to digital asset risks
News Market Reaction 26 Alerts
On the day this news was published, LIXT declined 16.29%, reflecting a significant negative market reaction. Argus tracked a trough of -32.8% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $26M at that time.
Data tracked by StockTitan Argus on the day of publication.
PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital allocation initiative to acquire cryptocurrency as part of its corporate treasury. The Board approved allocation of up to 25 percent of its treasury to cryptocurrencies, including Bitcoin and potentially other digital assets as it deems appropriate.
The timing and size of any such transactions will depend on prevailing market conditions and other strategic considerations. LIXTE will continue to closely monitor developments in the digital asset space and retains the flexibility to adjust its holdings.
The Company intends to hold all cryptocurrency assets with a fully regulated and compliant custodian. All future transactions will adhere strictly to applicable financial, legal and audit regulations to ensure transparency, security and full regulatory compliance.
“LIXTE’s updated treasury policy is based on our conviction in the long-term potential of cryptocurrency to hedge our existing treasury assets, as well as delivering meaningful returns for shareholders,” said Geordan Pursglove, Chairman and Chief Executive Officer of LIXTE. “This initiative also reflects the Board’s broader vision for LIXTE’s growth and commitment to enhancing long-term shareholder value.”
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
How much of LIXTE Biotechnology's (LIXT) treasury will be allocated to cryptocurrency?
What is the purpose of LIXTE's (LIXT) cryptocurrency investment strategy?
How will LIXTE (LIXT) manage its cryptocurrency holdings?
Who approved LIXTE Biotechnology's (LIXT) cryptocurrency treasury policy?
When will LIXTE (LIXT) begin purchasing cryptocurrency?
